Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Venous Thromboembolism Treatment Market

Venous Thromboembolism Treatment Market Size By Device (Compression System, Thrombectomy Systems, IVC Filters, Stockings), By Application (Deep Vein Thrombosis, Pulmonary Embolism), By End-use (Hospitals, Catheterization Laboratories), COVID-19 Impact Analysis, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2021 - 2027

  • Report ID: GMI3929
  • Published Date: Apr 2021
  • Report Format: PDF

Venous Thromboembolism Treatment Market Size

Venous Thromboembolism Treatment Market size exceeded USD 950 million in 2020 and is expected to expand at over 8.7% CAGR from 2021 to 2027. There is growing pervasiveness of cardiovascular diseases (CVD) and cancer owing to adoption of smoking, alcohol, increasing obesity rate, lack of physical activity and consumption of high cholesterol food. Vascular diseases and cancer patients possess high risk of having venous thromboembolism (VTE). Cancer patients have higher chance of developing blood clots with treatment procedures along with associated heredity.

Venous Thromboembolism Treatment Market Overview

Deep vein thrombosis is an ailment wherein blood clot is developed usually in the deep veins of the upper and lower limbs. These clots may travel through the circulation and get lodged in the lungs; leading to a condition known as pulmonary embolism (PE). This condition altogether known as venous thromboembolism (VTE), may be fatal and can potentially lead to death. Thus, VTE needs to be addressed on time. There are several treatment devices including filters, compression devices, thrombectomy systems among others that are used to treat VTE and with growing disease prevalence, their acceptance will potentially spur in the coming years.

Emergence of several mechanical and surgical treatment therapies will offer a lucrative venous thromboembolism treatment market growth opportunities

VTE is a potentially dangerous condition and if it is not treated at appropriate time, it may lead to complications and death. As per the Centres for Disease Control and Prevention (CDC), around 60,000-100,000 people in the U.S. die owing to venous thromboembolism. Also, blood clots are usually and primarily managed by drug therapy. However, sometimes, patient may require surgical intervention and mechanical devices to manage and treat the condition more effectively. Thus, with market leaders introducing novel devices, the end-users will have broader range of treatment options, thereby presenting lucrative growth opportunities during the forecast timeframe. However, lack of sufficient awareness and complications led by stent placement may limit the market expansion up to some extent.

Venous Thromboembolism Treatment Market Analysis

Compression system segment in the venous thromboembolism treatment market accounted for more than USD 120 million in 2020. Increasing number of surgical procedures has spurred the adoption of compression devices for DVT prophylaxis. Surgeries including orthopedic procedures cause long duration of immobility and thus, there is higher probability of development of DVT. Hence, patients are recommended to use compression devices post-procedure to curb the risk.

Venous Thromboembolism Treatment Market Size

Venous thromboembolism treatment market for Pulmonary embolism segment is projected to witness a 9.4% growth rate by 2027. PE is life-threatening and the 3rd most commonly affected CVD. Hence, market players are launching novel devices including ultrasound-guided catheter-directed thrombolysis systems to cater to need for effective treatment. Thus, with rising need for disease management, the demand for pulmonary embolism treatment devices will expand over the coming years.

Hospitals end-use segment dominated around 75% of the venous thromboembolism treatment market share in 2020. Large number of surgical procedures and interventions carried out in hospitals boosts the demand for VTE prophylactic devices in these settings.

Hospitals have well-developed infrastructure and thereby, large base of patient admissions. Wide range of ailments including cancer are treated in hospitals and hence due to associated risk of VTE, these settings showcase higher demand for various VTE treatment products. In addition, growing prevalence of hospital-associated venous thromboembolism will further stimulate the market progression during the forecast period.

North America venous thromboembolism treatment market captured over 40% of revenue share in 2020. As per the American Medical Association, around 2 million Americans are affected by deep vein thrombosis annually. Thus, with increasing incidence of such fatal disease, its awareness, diagnosis and timely therapy is crucial.

Several organizations are taking initiatives to raise awareness about VTE in the country. Some organizations, in collaboration with the CDC, are joining the ‘Stop the Clot, Spread the Word’ campaign to spread national awareness about blood clots. Such initiatives will positively impact knowledge about disease diagnosis and treatment alternatives, thereby influencing the market value during the forecast timeline.

Venous Thromboembolism Treatment Market Share

Leading companies are undertaking the several venous thromboembolism treatment market expansion strategies such as:

  • Boston Scientific Corporation
  • AngioDynamics

  •  Cardinal Health

  • Covidien

  • Daesung Maref

  • Cook Medical

  •  Argon Medical Products

 of new treatment systems and acquisition of firms to fortify their portfolio and market position.

The venous thromboembolism treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2016 to 2027 for the following segments:

Click here to Buy Section of this Report

Market, By Device

  • Compression System
  • Thrombectomy Systems
  • IVC Filters
  • Stockings
  • Others

Market, By Application

  • Deep vein Thrombosis
  • Pulmonary Embolism

Market, By End-use

  • Hospitals
  • Catheterization Laboratories
  • Others

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
Authors: Mariam Faizullabhoy

Frequently Asked Questions (FAQ) :

The revenue share of the venous thromboembolism treatment industry was valued at USD 950 million in 2020 and will rise at a CAGR of over 8.7% up to 2027 with a higher prevalence of cardiovascular diseases (CVD) and cancer.

The market size from the compression system device segment reached USD 120 million in 2020 and will grow with increasing adoption across DVT prophylaxis.

The market revenue from pulmonary embolism applications is expected to observe a growth rate of 9.4% up to 2027 due to the increasing prevalence of the disease.

Hospitals accounted for over 75% of total revenue share in 2020 and will see higher expansion owing to the increase in the number of surgical procedures that require VTE prophylactic devices.

North America was responsible for over 40% of the venous thromboembolism treatment revenue share in 2020 due to the rise in the number of initiatives in the region.

Venous Thromboembolism Treatment Market Scope

Buy Now

Premium Report Details

  • Base Year: 2020
  • Companies covered: 7
  • Tables & Figures: 192
  • Countries covered: 18
  • Pages: 120
 Download PDF